Genmab (GMAB DC) sees FY profit between USD 3.81-4.11bln, sees FY EBIT between USD 0.9-1.4bln; sees FY operating expenses between USD 2.71-2.91bln

Genmab (GMAB DC) sees FY profit between USD 3.81-4.11bln, sees FY EBIT between USD 0.9-1.4bln; sees FY operating expenses between USD 2.71-2.91bln.

Genmab's projected FY profit and EBIT fall within a wide range, indicating potential volatility in expectations. The guidance for operating expenses adds further context, suggesting margins may be squeezed, which could impact investor sentiment and stock pricing. This outlook will be crucial to monitor for sector peers and market reactions as it highlights both growth potential and cost pressures.